Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.

ABSTRACT:

Importance

The doses of antipsychotic drugs needed for relapse prevention in schizophrenia is a debated issue.

Objective

To examine dose-response findings in a meta-analysis of randomized clinical trials.

Data sources

Studies were identified through the Cochrane Schizophrenia Group's Study-Based Register of Trials (March 9, 2020), PubMed (January 1, 2021), and previous reviews. First authors and/or pharmaceutical companies were contacted for additional information.

Study selection

Two reviewers independently selected randomized clinical trials that compared fixed doses of a second-generation antipsychotic, haloperidol, or fluphenazine for relapse prevention in patients with stable schizophrenia.

Data extraction and synthesis

Using the Preferred Reporting

SUBMITTER: Leucht S 

PROVIDER: S-EPMC8374744 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature